Faculty Opinions recommendation of Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study.

Author(s):  
Ralph Sacco ◽  
Sebastian Koch
Keyword(s):  
Praxis ◽  
2003 ◽  
Vol 92 (5) ◽  
pp. 168-178
Author(s):  
Baumgartner ◽  
Georgiadis

Ce travail de revue présente la prévention secondaire des accidents vasculaire cérébraux par le traitement des facteurs de risque vasculaire, les inhibiteurs de l'agrégation plaquettaire, l'anticoagulation ou les thérapies endovasculaires. Deux études publiées récemment (PROtection aGainst Recurrent Stroke Study (PROGRESS) et la Heart Protection Study (HPS) ont pour la première fois pu démontrer l'efficacité d'un traitement contre l'hypertension et par statines dans la prévention secondaire après un accident vasculaire cérébral. PROGRESS a montré que la combinaison de perindopril et d'indapamide permet de réduire de 43% la survenue d'accidents vasculaires cérébraux ischémiques et hémorragiques chez les patients hypertendus ou normotendus alors que HPS a mis en évidence une diminution de 20% des accidents vasculaires cérébraux ischémiques chez les patients avec des taux sériques normaux ou élevés de cholestérol. Les sténoses carotidiennes symptomatiques avec un resserrement distal > ou égal à 70% sont opérées par endartérectomie; en cas de sténose distale de 50–69% une décision individuelle est prise; une endartérectomie n'est pas indiquée en cas de sténose < 50%. Les patients chez lesquels une source cardiaque d'embolie est mise en évidence doivent être anticoagulés (INR 2.5, intervalle: 2–3) à l'exception des myxomes cardiaques et des endocardites bactériennes. Si aucune intervention chirurgicale sur une artère cérébrale n'est indiquée ou si le patient ne doit pas être anticoagulé, on traite par un inhibiteur de l'agrégation plaquettaire: 100 mg d'aspirine ou la combinaison d'aspirine et de dipyridamol sont le traitement de choix. En cas de récidive d'ischémie sous aspirine ou d'intolérance à l'aspirine, le clopidogrel est prescrit. Comme alternative au clopidogrel en cas de récidive d'ischémie, une anticoagulation (INR 2.0, intervalle: 1.5–2.5) peut être prescrite.


2020 ◽  
Vol 91 (4) ◽  
pp. 352-357
Author(s):  
Jessica Tedford ◽  
Valerie Skaggs ◽  
Ann Norris ◽  
Farhad Sahiar ◽  
Charles Mathers

INTRODUCTION: Atrial fibrillation (AF) is one of the most common cardiac arrhythmias in the general population and is considered disqualifying aeromedically. This study is a unique examination of significant outcomes in aviators with previous history of both AF and stroke.METHODS: Pilots examined by the FAA between 2002 and 2012 who had had AF at some point during his or her medical history were reviewed, and those with an initial stroke or transient ischemic attack (TIA) during that time period were included in this study. All records were individually reviewed to determine stroke and AF history, medical certification history, and recurrent events. Variables collected included medical and behavior history, stroke type, gender, BMI, medication use, and any cardiovascular or neurological outcomes of interest. Major recurrent events included stroke, TIA, cerebrovascular accident, death, or other major events. These factors were used to calculate CHA2DS2-VASc scores.RESULTS: Of the 141 pilots selected for the study, 17.7% experienced a recurrent event. At 6 mo, the recurrent event rate was 5.0%; at 1 yr, 5.8%; at 3 yr 6.9%; and at 5 yr the recurrent event rate was 17.3%. No statistical difference between CHA2DS2-VASc scores was found as it pertained to number of recurrent events.DISCUSSION: We found no significant factors predicting risk of recurrent event and lower recurrence rates in pilots than the general population. This suggests CHA2DS2-VASc scores are not appropriate risk stratification tools in an aviation population and more research is necessary to determine risk of recurrent events in aviators with atrial fibrillation.Tedford J, Skaggs V, Norris A, Sahiar F, Mathers C. Recurrent stroke risk in pilots with atrial fibrillation. Aerosp Med Hum Perform. 2020; 91(4):352–357.


2016 ◽  
Vol 18 (9) ◽  
pp. 8-11 ◽  
Author(s):  
L.V. Stakhovskaya ◽  
◽  
O.A. Klochikhina ◽  
M.D. Bogatyreva ◽  
S.A. Chugunova ◽  
...  

2019 ◽  
Author(s):  
Emre Kumral ◽  
Can Emre Erdoğan ◽  
Abdullah Arı ◽  
Fatma Ece Bayam ◽  
Gülsüm Saruhan

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A Bielecka-Dabrowa ◽  
P Gasiorek ◽  
A Sakowicz ◽  
M Banach

Abstract Purpose The study aimed to identify echocardiographic, hemodynamic and biochemical predictors of unfavourable prognosis after ischemic strokes of undetermined etiology (ESUS) in patients (pts) at age <65. Methods Out of 520 ischemic stroke pts we selected 64 pts diagnosed with ESUS [mean age 54 (SD: 47–58) years, 42% males] and additional 36 without stroke but with similar risk profile, which were treated as a reference group [age 53 (SD: 47–58) years, 61% males]. All pts underwent echocardiography, non-invasive assessment of hemodynamic parameters using SphygmoCor tonometer (Atcor Med., Australia), HDL subfraction distribution using Lipoprint (Quantimetrix) as well as measurements of selected biomarkers. Follow-up was 12 months. Results At 12-month follow-up 9% of patients had died, and recurrent ischemic stroke also occurred in 9% of patients - only in the ESUS group (Figure). Patients who died had significantly lower levels of LDL and HDL cholesterol (included HDL-8 and -9 subfractions) and higher level of triglicerides (p=0.01, p=0.01, and p=0.02; respectively), lower level of adiponectin (p=0.01), lower value of mean early diastolic (E') mitral annular velocity (p=0.04) and lower diastolic blood pressure (p=0.04). The atrial fibrillation (AF) occurred in 10% of pts during the 12 months (log-rang, p=0.254) (Figure). The log-rank test showed that ESUS group had a significantly poorer outcome of AF in the first 2 months after hospitalization compared to reference group (11% vs 5%, p=0.041). Based on a Kaplan-Meier analysis, the outcome of re-hospitalizationin the 1st year was 28% (18/64) in the ESUS group and 17% (6/36); log-rank, p=0.058. In the multivariate analysis mean early diastolic (E') mitral annular velocity (odds ratio [OR] 0.75, 95% confidence interval [CI]: 0.6–0.94; p=0.01) was significantly associated with CV hospitalizations assessed at 12-month follow-up. The only independent predictor of AF occurrence in the 12-month follow-up was lower value of Tissue Doppler-derived right ventricular systolic excursion velocity S' (OR 0.65, 95% Cl 0.45–0.93; p=0.01). The only independent predictor of recurrent stroke was the ratio of peak velocity of early diastolic transmitral flow to peak velocity of early diastolic mitral annular motion as determined by pulsed wave Doppler (E/E') (OR 0.75, 95% CI: 0.6–0.94; p=0.01). E/E' ratio was also independently associated with composite endpoint consisting of death, hospitalization and recurrent stroke (OR 1.90, 95% CI 1.1–3.2, p=0.01). Kaplan-Meier Analysis - survival and AF Conclusions The indices of diastolic dysfunction are significantly associated with unfavourable prognosis after ESUS. There is a robust role for outpatient cardiac monitoring especially during first 2 months after ESUS to detect potential AF. Acknowledgement/Funding The study was financed by research grants no. 502-03/5-139-02/502-54-229-18 of the Medical University of Lodz


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 661.2-661
Author(s):  
C. Belizna ◽  
O. Latino ◽  
L. Stojanovich ◽  
P. Saulnier ◽  
K. Devreese ◽  
...  

Background:Although guidelines do not recommend antiphospholipid antibodies testing after 60 yo, recent data reported late onset antiphospholipid syndrome (APS).Objectives:To comparatively analyse the clinical, laboratory features and outcomes in 695 cases with primary APS between patients older and younger than 70 yo.Methods:we have performed an international study within the framework of the International Registry of primary APS patients treated with Hydroxychloroquine, HIBISCUS (an ongoing retrospective and prospective register launched in 2016). 28 centres from 17 countries participate. Data about late onset APS were analysed in 695 patients and were obtained from a standardized form registered in the database containing 66 items with respect to demographics, clinical and biological features.Results:Arterial events and especially stroke represented the main initial and recurrent clinical manifestation in 40 primary APS patients older than 70 yo. There were not statistically significant differences with respect to cardiovascular risk factors between the two groups of patients. A significant male predominance, a familial APS history, a higher prevalence of triple positivity, lower complement levels, and anticardiolipin antibodies (aCL) IgA isotype were found in older patients. Low anticoagulation regimens were safe and efficient, with a low relapse rate in older patients.Conclusion:we suggest that the detection of aPL antibodies should be included into the initial screening panel tests in elderly with thrombotic events, especially arterial, in particular those with recurrent stroke and familial APS.Our study further suggests that lower intensity anticoagulation regimens could be a therapeutic option in older APS patients, as no differences in outcomes and relapse rate were found between patients with high and low intensity anticoagulation regimens.References:[1]Grimaud F et al. Rheumatology. 2019;58:1006-10.[2]Goldman-Mazur S et al. Thromb Res. 2019;176:67-73.[3]Hirmerova J et al. 2017;36:167-73.Disclosure of Interests:Cristina Belizna: None declared, Omar Latino: None declared, Ljudmila Stojanovich: None declared, Patrick Saulnier: None declared, Katrien Devreese: None declared, Sebastien Udry: None declared, Natasa Stanisavljevic: None declared, Aleksandra Djokovic Speakers bureau: KRKA, Astra Zeneca, Actavis, Jaume Alijotas-Reig: None declared, Enrique Esteve-Valverde: None declared, Raquel Ferrer-Oliveras: None declared, Angela Tincani: None declared, Laura Andreoli: None declared, Francesca Regola: None declared, Maarten Limper: None declared, Alexander Makatsariya: None declared, Jamilya Khizroeva: None declared, Viktoria Bitsadze: None declared, Cecilia Chighizola: None declared, Francesca Pregnolato: None declared, Maria Orietta Borghi: None declared, Pier Luigi Meroni: None declared


2021 ◽  
Vol 20 (6) ◽  
pp. 437-447 ◽  
Author(s):  
Linxin Li ◽  
Michael T C Poon ◽  
Neshika E Samarasekera ◽  
Luke A Perry ◽  
Tom J Moullaali ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document